Industry News
Biotechnology Industry News

Investors flip-flop on Nykode’s cancer vaccine data drop
Investors flip-flop on Nykode's cancer vaccine data drop ntaylor Mon, 05/09/2022 - 06:36
Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect
Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect ntaylor Mon, 05/09/2022 - 05:31
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety mbayer Fri, 05/06/2022 - 10:32
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
With Sarepta in its sights, PepGen prices IPO to fund DMD trials ntaylor Fri, 05/06/2022 - 07:16
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelm
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelm ntaylor Fri, 05/06/2022 - 06:14
Orion aims to challenge Vertex with new pain management licensing deal
Orion aims to challenge Vertex with new pain management licensing deal jwaldron Fri, 05/06/2022 - 06:02
After layoffs, BridgeBio turns to dealmaking for up to 6 drugs
After layoffs, BridgeBio turns to dealmaking for up to 6 drugs gmasson Thu, 05/05/2022 - 14:20
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul following Aduhelm blunder
Chutes & Ladders—Biogen CEO Vounatsos steps down amid company overhaul following Aduhelm blunder mbayer Thu, 05/05/2022 - 13:26
Intellia puts pedal to the metal as 3 new candidates prepped for clinic
Intellia puts pedal to the metal as 3 new candidates prepped for clinic aarmstrong Thu, 05/05/2022 - 10:26
BioCryst’s voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signals
BioCryst's voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signals mbayer Thu, 05/05/2022 - 10:21
Big pharma resisting temptation for biotech M&A spree until prices drop further
Big pharma resisting temptation for biotech M&A spree until prices drop further jwaldron Thu, 05/05/2022 - 09:53
Bavarian Nordic’s COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push
Bavarian Nordic's COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push ntaylor Thu, 05/05/2022 - 08:54
Jazz flexes deal chops, paying Sumitomo $50M for ex-Asia rights to early-phase narcolepsy prospect
Jazz flexes deal chops, paying Sumitomo $50M for ex-Asia rights to early-phase narcolepsy prospect ntaylor Thu, 05/05/2022 - 08:05
BerGenBio shifts focus from COVID—to COVID in new business strategy update
BerGenBio shifts focus from COVID—to COVID in new business strategy update aarmstrong Wed, 05/04/2022 - 13:57
Bancel has ‘never been as busy’ amid M&A talks as Moderna preps for life after COVID
Bancel has 'never been as busy' amid M&A talks as Moderna preps for life after COVID mbayer Wed, 05/04/2022 - 10:41
Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug
Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug gmasson Wed, 05/04/2022 - 10:24
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug vision
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug vision ntaylor Wed, 05/04/2022 - 09:28
Catalio reloads with $381M after financing Octant, Pheast
Catalio reloads with $381M after financing Octant, Pheast aarmstrong Wed, 05/04/2022 - 09:23
Biogen shoves Aduhelm to the side. It’s time for lecanemab
Biogen shoves Aduhelm to the side. It's time for lecanemab aarmstrong Wed, 05/04/2022 - 08:22
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forward ntaylor Wed, 05/04/2022 - 07:54

